Agenus Company Profile (NASDAQ:AGEN)

About Agenus (NASDAQ:AGEN)

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Symbol: NASDAQ:AGEN
CUSIP: 00847G70
Web: www.agenusbio.com

Capitalization:

Market Cap: $337 million
Outstanding Shares: 99,118,000

Average Prices:

50 Day Moving Avg: $3.58
200 Day Moving Avg: $4.06
52 Week Range: $3.20 - $7.49

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.28
P/E Growth: 0.000

Sales & Book Value:

Annual Revenue: $43.57 million
Price / Sales: 7.73
Book Value: $0.09 per share
Price / Book: 37.78

Profitability:

EBIDTA: ($85,440,000.00)
Net Margins: -472.80%
Return on Equity: -359.98%
Return on Assets: -47.88%

Debt:

Debt-to-Equity Ratio: -6.00%
Current Ratio: 3.14%
Quick Ratio: 3.14%

Misc:

Average Volume: 1.11 million shs.
Beta: 2.51
Short Ratio: 8.52

Frequently Asked Questions for Agenus (NASDAQ:AGEN)

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. The firm earned $26.96 million during the quarter, compared to analysts' expectations of $5.22 million. Agenus had a negative net margin of 472.80% and a negative return on equity of 359.98%. View Agenus' Earnings History.

When will Agenus make its next earnings announcement?

Agenus is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Agenus.

Where is Agenus' stock going? Where will Agenus' stock price be in 2017?

4 equities research analysts have issued 1 year target prices for Agenus' stock. Their forecasts range from $5.00 to $7.00. On average, they anticipate Agenus' share price to reach $6.33 in the next twelve months. View Analyst Ratings for Agenus.

What are analysts saying about Agenus stock?

Here are some recent quotes from research analysts about Agenus stock:

1. According to Zacks Investment Research, "Agenus focuses on the development of checkpoint modulators, vaccines and adjuvants for cancer treatments. With no approved product in its portfolio, the company is heavily dependent on its collaborators for top-line growth. In addition, the company is dependent on its partners for pipeline development. Moreover, Agenus has few candidates in mid-stage of development including Prophage vaccine and several QS-21 Stimulon-containing vaccine candidates. Any unfavorable outcome from the studies may affect the company’s shares adversely. However, the company received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. Moreover, the company’s collaboration agreements provide a steady source of funds. Agenus’ shares have outperformed the Medical/Biomedical Genetics industry." (12/27/2016)
2. Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)

Who are some of Agenus' key competitors?

Some companies that are related to Agenus include MacroGenics (MGNX), Aclaris Therapeutics (ACRS), Cytokinetics (CYTK), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Enanta Pharmaceuticals (ENTA), Paratek Pharmaceuticals (PRTK), Calithera Biosciences (CALA), Cara Therapeutics (CARA), Achillion Pharmaceuticals (ACHN), Regenxbio (RGNX), Neuroderm Ltd (NDRM), ANI Pharmaceuticals (ANIP), CytomX Therapeutics (CTMX), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Adaptimmune Therapeutics PLC - (ADAP) and Progenics Pharmaceuticals (PGNX).

Who owns Agenus stock?

Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Oracle Investment Management Inc. (1.72%), FMR LLC (0.00%), Goldman Sachs Group Inc. (0.68%), Bank of New York Mellon Corp (0.57%) and Geode Capital Management LLC (0.00%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

Who sold Agenus stock? Who is selling Agenus stock?

Agenus' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, FMR LLC, Alliancebernstein L.P., TIAA CREF Investment Management LLC, California Public Employees Retirement System and Nationwide Fund Advisors. View Insider Buying and Selling for Agenus.

Who bought Agenus stock? Who is buying Agenus stock?

Agenus' stock was acquired by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Goldman Sachs Group Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., Bank of New York Mellon Corp, Chicago Equity Partners LLC and Highbridge Capital Management LLC. Company insiders that have bought Agenus stock in the last two years include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Insider Buying and Selling for Agenus.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agenus stock cost?

One share of Agenus stock can currently be purchased for approximately $3.40.

Consensus Ratings for Agenus (NASDAQ:AGEN) (?)

Ratings Breakdown:	1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.75)
Consensus Price Target:	$6.33 (86.27% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
5/6/2017	HC Wainwright	Set Price Target	Hold	$5.00	Low
4/23/2017	Maxim Group	Reiterated Rating	Buy	$7.00	Medium
12/1/2016	JMP Securities	Reiterated Rating	Buy		N/A
8/23/2016	Jefferies Group LLC	Reiterated Rating	Buy		N/A
3/9/2016	JPMorgan Chase & Co.	Lower Price Target	Market Outperform	$17.00 -> $15.00	N/A
12/31/2015	Oppenheimer Holdings Inc.	Reiterated Rating	Positive -> Outperform	$14.00	N/A
9/10/2015	William Blair	Reiterated Rating	Buy		N/A
7/27/2015	MLV & Co.	Reiterated Rating	Buy	$9.00 -> $11.00	N/A

(Data available from 5/23/2015 forward)

Earnings History for Agenus (NASDAQ:AGEN)

Earnings by Quarter for Agenus (NASDAQ:AGEN)

Earnings History by Quarter for Agenus (NASDAQ:AGEN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/26/2017
5/4/2017	Q1 2017	($0.32)	($0.18)	$5.22 million	$26.96 million	View	Listen
3/9/2017	Q4 2016	($0.30)	($0.30)	$6.01 million	$5.58 million	View	Listen
10/27/2016	Q316	($0.32)	($0.47)	$6.15 million	$4.45 million	View	Listen
7/28/2016	Q216	($0.34)	($0.33)	$5.12 million	$6.59 million	View	Listen
4/28/2016	Q116	($0.23)	($0.37)	$6.74 million	$5.96 million	View	Listen
3/3/2016	Q415	($0.17)	($0.18)	$9.39 million	$7.64 million	View	Listen
10/27/2015	Q315	($0.15)	($0.16)	$5.71 million	$6.85 million	View	Listen
7/23/2015	Q215	($0.15)	($0.44)	$5.71 million	$6.38 million	View	Listen
4/23/2015	Q115	($0.15)	($0.21)	$11.66 million	$3.95 million	View	N/A
2/26/2015	Q414	($0.15)	($0.18)	$0.66 million	$1.62 million	View	N/A
10/31/2014	Q314	($0.15)	($0.13)	$1.96 million	$1.56 million	View	N/A
7/24/2014	Q214	($0.11)	($0.12)	$0.71 million	$3.07 million	View	N/A
5/8/2014	Q114	($0.16)	$0.01	$0.55 million	$0.72 million	View	N/A
3/5/2014	Q413	($0.24)	($0.16)	$870.00 million	$393.00 million	View	N/A
10/24/2013	Q313	($0.27)	($0.24)		$736.00 million	View	N/A
7/25/2013	Q2 2013	($0.21)	($0.40)			View	N/A
2/28/2013	Q4 2012	($0.24)	($0.23)	$0.72 million	$1.09 million	View	N/A
7/28/2011		($0.05)	($0.05)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Agenus (NASDAQ:AGEN)

2017 EPS Consensus Estimate: ($1.09)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	($0.33)	($0.24)	($0.29)
Q2 2017	2	($0.30)	($0.24)	($0.27)
Q3 2017	2	($0.31)	($0.25)	($0.28)
Q4 2017	1	($0.25)	($0.25)	($0.25)

(Data provided by Zacks Investment Research)

Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 45.40%

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Insider Trades by Quarter for Agenus (NASDAQ:AGEN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/12/2017	Garo H Armen	CEO	Buy	100,000	$3.35	$335,000.00
2/14/2017	Corp Incyte	Major Shareholder	Buy	10,000,000	$6.00	$60,000,000.00
9/6/2016	Ulf Wiinberg	Director	Buy	30,000	$6.29	$188,700.00
5/9/2016	Garo H Armen	CEO	Buy	100,000	$3.18	$318,000.00
5/5/2016	Ozer Baysal	Insider	Buy	2,250	$3.10	$6,975.00
3/7/2016	Garo H Armen	CEO	Buy	200,000	$4.03	$806,000.00
12/29/2015	Garo H. Armen	CEO	Sell	219,576	$4.59	$1,007,853.84
12/28/2015	Garo H. Armen	CEO	Sell	134,352	$4.60	$618,019.20
9/25/2015	Charles Evan Ballantyne	CFO	Buy	10,000	$5.05	$50,500.00
9/25/2015	Garo H Armen	CEO	Buy	100,000	$5.03	$503,000.00
4/29/2015	Shahzad Malik	Director	Sell	1,107,377	$7.11	$7,873,450.47
1/9/2015	Qvt Associates Gp Llc	Major Shareholder	Sell	2,343,630	$5.31	$12,444,675.30
1/23/2014	Karen Valentine	VP	Sell	2,850	$3.50	$9,975.00

(Data available from 1/1/2013 forward)

Headline Trends for Agenus (NASDAQ:AGEN) Latest Headlines for Agenus (NASDAQ:AGEN)

Source:

Date	Headline
	Agenus to present safety results for anti-CTLA-4 antibody at ASCO ... - PR Newswire (press release) www.prnewswire.com - May 22 at 3:24 PM
	Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting finance.yahoo.com - May 22 at 3:24 PM
	ETFs with exposure to Agenus, Inc. : May 22, 2017 finance.yahoo.com - May 22 at 3:24 PM
	Research Reports Initiation on Biotech Stocks -- Agenus, Athersys ... - PR Newswire (press release) www.prnewswire.com - May 19 at 3:24 PM
	ETFs with exposure to Agenus, Inc. : May 11, 2017 finance.yahoo.com - May 11 at 8:48 PM
	$5.19 Million in Sales Expected for Agenus Inc (AGEN) This Quarter www.americanbankingnews.com - May 10 at 9:16 AM
	Agenus, Inc. :AGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 finance.yahoo.com - May 9 at 3:23 PM
	Brokerages Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.31 Per Share www.americanbankingnews.com - May 8 at 10:27 PM
	Agenus, Inc. – Value Analysis (NASDAQ:AGEN) : May 8, 2017 finance.yahoo.com - May 8 at 8:47 PM
	Agenus Stock Bounces on Q1 Report, Update www.baystreet.ca - May 5 at 8:25 PM
	Agenus Inc (AGEN) Announces Quarterly Earnings Results www.americanbankingnews.com - May 5 at 3:58 PM
	Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1 - Nasdaq www.nasdaq.com - May 5 at 3:24 PM
	Agenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : May 5, 2017 finance.yahoo.com - May 5 at 3:24 PM
	Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1 finance.yahoo.com - May 5 at 3:24 PM
	BRIEF-Agenus Q1 loss per share $0.18 www.reuters.com - May 4 at 8:26 PM
	Here's Why Agenus Inc. Stock Is Climbing Today www.fool.com - May 4 at 8:26 PM
	Investor Network: Agenus Inc. to Host Earnings Call finance.yahoo.com - May 4 at 8:26 PM
	Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update finance.yahoo.com - May 4 at 8:26 PM
	Here's Why Agenus Inc. Stock Is Climbing Today finance.yahoo.com - May 4 at 8:26 PM
	Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release) www.prnewswire.com - May 4 at 3:24 PM
	Agenus (AGEN) Reports Narrower-than-Expected Q1 Loss finance.yahoo.com - May 4 at 3:24 PM
	Agenus reports 1Q loss marketbeat.com - May 4 at 9:12 AM
	Somewhat Positive Press Coverage Extremely Likely to Affect Agenus (AGEN) Share Price www.americanbankingnews.com - May 3 at 10:15 AM
	Agenus Inc (AGEN) Scheduled to Post Quarterly Earnings on Thursday www.americanbankingnews.com - May 2 at 7:28 AM
	Array Biopharma (ARRY) Appoints Shalini Sharp to Board www.streetinsider.com - April 27 at 8:43 PM
	Shalini Sharp Joins Array BioPharma Board of Directors www.bizjournals.com - April 27 at 3:43 PM
	Agenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow finance.yahoo.com - April 27 at 3:43 PM
	Agenus (AGEN) Receiving Somewhat Negative News Coverage, Analysis Shows www.americanbankingnews.com - April 26 at 1:50 PM
	What's in Store for Agenus (AGEN) this Earnings Season? www.nasdaq.com - April 24 at 3:26 PM
	First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus finance.yahoo.com - April 24 at 3:26 PM
	Agenus Inc to Post FY2019 Earnings of ($1.34) Per Share, William Blair Forecasts (AGEN) www.americanbankingnews.com - April 24 at 12:27 PM
	What's in Store for Agenus (AGEN) this Earnings Season? - Yahoo Finance finance.yahoo.com - April 24 at 10:58 AM
	What's in Store for Agenus (AGEN) this Earnings Season? finance.yahoo.com - April 24 at 10:58 AM
	Agenus Inc (AGEN) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - April 24 at 7:52 AM
	Agenus Inc (AGEN) Rating Reiterated by Maxim Group www.americanbankingnews.com - April 23 at 10:26 AM
	Somewhat Favorable News Coverage Extremely Likely to Impact Agenus (AGEN) Stock Price www.americanbankingnews.com - April 23 at 7:46 AM
	Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins - PR Newswire (press release) www.prnewswire.com - April 21 at 3:22 PM
	BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins www.reuters.com - April 21 at 1:28 AM
	Form 8-K AGENUS INC For: Apr 20 - StreetInsider.com www.streetinsider.com - April 20 at 3:25 PM
	Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins finance.yahoo.com - April 20 at 3:24 PM
	Agenus (AGEN) Receiving Somewhat Favorable Press Coverage, Analysis Finds www.americanbankingnews.com - April 20 at 10:47 AM
	Analysts Anticipate Agenus Inc (AGEN) Will Announce Quarterly Sales of $5.06 Million www.americanbankingnews.com - April 19 at 9:25 AM
	Agenus Inc (AGEN) Expected to Announce Earnings of -$0.32 Per Share www.americanbankingnews.com - April 18 at 12:09 AM
	Agenus (AGEN) Receives Coverage Optimism Score of 0.13 www.americanbankingnews.com - April 15 at 8:53 AM
	Insider Buying: Agenus Inc (AGEN) CEO Buys 100,000 Shares of Stock www.americanbankingnews.com - April 13 at 8:02 AM
	Why Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report? - Nasdaq www.nasdaq.com - April 11 at 8:23 AM
	Why Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report? finance.yahoo.com - April 11 at 8:23 AM
	ETFs with exposure to Agenus, Inc. : April 10, 2017 finance.yahoo.com - April 10 at 3:23 PM
	Agenus Inc (AGEN) Short Interest Update www.americanbankingnews.com - April 8 at 7:26 AM
	BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax www.reuters.com - April 7 at 3:23 PM